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Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic
renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the
outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center.
In the light of the retrospective, observational nature and the unselected population,
our experience can be defined a “real-world” study. The medical records of 38 mRCC
patients treated with front-line pazopanib were retrospectively reviewed and analyzed.
The progression free survival (PFS) and the overall survival (OS) were the primary
endpoints, while secondary objectives included objective response rate (ORR), disease
control rate (DCR), and treatment tolerability. Pazopanib achieved a median PFS (mPFS)
of 12.7 months (95% CI, 6.9–18.5 months). The median OS (mOS) was 26.2 months
(95% CI, 12.6–39.9 months); the observed ORR and DCR were 30.3 and 72.7%,
respectively, with a median duration of response of 11 weeks. mPFS appeared not to
be influenced by number of co-morbidities (<3 vs. ≥3), gender, Fuhrman grade and
age. Conversely, the ORR and the DCR positively affect the mPFS (HR = 0.05 [95% CI,
0.05–0.55], p = 0.01; HR = 0.10 [95% CI, 0.02–0.43], p = 0.002, respectively). A worse
outcome was associated with a lower mPFS in patients with liver metastases (p = 0.2)
and with a high tumor burden (number of metastatic sites <6 vs. ≥6) (p = 0.08). Worst
OS was observed in patients aged ≥70 years old (HR = 6.91 [95% CI, 1.49–31.91], p =
0.01). The treatment was well-tolerated: no grade 4 adverse events, nor discontinuation
due to toxicities was reported. Grade 3 hypertension affected positively the OS reaching
the statistical significance (HR= 0.22 [95% CI, 0.05–0.8 ], p= 0.03). Thyroid dysfunction
(hypo and hyperthyroidism) seems to correlate with better outcome in terms of a longer
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mPFS (HR = 0.12 [95% CI, 0.02–0.78], p = 0.02). Our results are consistent with
those reported in prospective phase III trials and the published retrospective “real world”
experiences. This analysis confirms the safety and efficacy of pazopanib in first-line
setting, both in frail patients with multiple co-morbidities and Karnofsky PS <80% and
in younger, healthier patients with a number of metastatic sites <6.
Keywords: mRCC, first-line, pazopanib, real-life, PFS
INTRODUCTION
Renal cell carcinoma (RCC), is the most common subtype of
kidney cancer (Choueiri, 2011). Approximately 90% of these
tumors are classified as RCC and up to 80% as “clear cell” RCC
(Janzen et al., 2003; Choueiri, 2011). Most patients (>75%) are
diagnosed when the disease is already advanced or metastatic,
mRCC, hence no more curable (Facchini et al., 2009). Recurrent
and/or mRCC is associated with a poor 5-years survival, roughly
10%; however, in the last decade, a series of novel agents have
been introduced in clinical practice and the outcomes are slowly
improving. Despite an increasing knowledge about the genetic
and signaling abnormalities involved in the RCC carcinogenesis,
such as VHL, PBRM1, SETD2, and BAP1 genes, no biomarkers
are currently available, thus there are no molecular factors, which
may guide the clinicians in choosing the therapeutic strategy
(Brugarolas, 2014).
The advent of the target therapies (TTs) has revolutionized
the mRCC treatment with an impressive effect on the overall
survival (OS), which increased from an average of 9 months in
1995, when the only option in first-line was interferon alfa (IFN-
α), to a median of 28–29 months in 2013, the TTs era (Motzer
and Russo, 2000; Chowdhury et al., 2008; Albiges et al., 2015;
de Velasco et al., 2015). The TTs include the tyrosine kinase
inhibitors (TKIs), targeting the vascular endothelial growth
factor receptors (VEGFRs), the mammalian target of rapamycin
inhibitors (mTORis), and bevacizumab, a monoclonal antibody
targeting the VEGF ligand.
Sunitinib, a TKI targeting the angiogenesis, is currently
considered the standard therapy in newly diagnosed, mRCC
patients, who have a good-intermediate prognosis (Albiges et al.,
2015). Nevertheless, pazopanib (PAZ), a multi-targeted TKI, has
been recently approved in first-line mRCC treatment and in
second-line, after treatment with cytokines. The approval comes
from the results of the phase III, pivotal trial that compared
PAZ to placebo in a heterogeneous population, including
both therapy-naïve and cytokine-pretreated patients. PFS was
significantly prolonged in the PAZ arm, in the first-line subset
(median 11.1 vs. 2.8 months; p< 0.0001) as well as in the second-
line setting (median, 7.4 vs. 4.2 months; p < 0.001) and in the
overall cohort (median, 9.2 vs. 4.2 months; p < 0.0001); the
median OS was 22.9 months with PAZ and 20.5 months with
placebo, with an ORR of 30 vs. 3% with placebo (Sternberg et al.,
2010).
Abbreviations: RCC, renal cell carcinoma; TT, targeted therapy; OS, overall
survival; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor
receptor; PAZ, pazopanib.
A large non-inferiority study, the COMPARZ, compared
PAZ to sunitinib in first-line, showing no statistically significant
difference in terms of PFS, OS, and response rate (RR), with a
slightly different toxicity profile in favor of PAZ (Motzer et al.,
2013a). Subsequently, the PISCES (Patient Preference Study of
PAZ vs. Sunitinib in Advanced orMetastatic Kidney Cancer) trial
confirmed that PAZ had a better safety profile and was associated
to a better quality of life, compared to sunitinib (Escudier et al.,
2014).
Although some authors have questioned the results of the
above-mentioned studies, the evidences are robust enough to
support the use of PAZ in first-line as valuable alternative
to sunitinib. To date there are not validated prognostic and
predictive biomarkers of response, and none of the available
studies has provided any straight, unbiased factor, which might
guide the clinician in choosing PAZ rather than sunitinib, or
vice versa. In the front-line setting, hence the decision is made
exclusively on the basis of the safety profile and patients medical
history; in particular, PAZ is generally preferred in patients with
severe cardiovascular co-morbidities or poor performance status
(D’Alterio et al., 2010, 2012; Sonpavde et al., 2012; Choueiri et al.,
2013; Ravaud et al., 2013; D’Aniello et al., 2014; Cavaliere et al.,
2015).
Several “real world” studies have showed the efficacy and
safety of PAZ in unselected populations (Galvis et al., 2013;
Matrana et al., 2013a; Jonasch et al., 2014; Rizzo et al., 2015;
Vogelzang et al., 2015), we thought to further reinforce such
evidences publishing our own experience with the drug.
MATERIALS AND METHODS
Patients
This is a mono-institutional, observational, retrospective study,
which was carried out in the Department of Uro-Gynecological
Oncology of the National Cancer Institute of Naples, Italy,
after approval by the National Cancer Institute of Naples
Institutional Board. The study was carried out in accordance
with the recommendations of the local review board with written
informed consent from all subjects. All subjects gave written
informed consent in accordance with the Declaration of Helsinki.
We retrieved from our archive the medical records of all the
patients with mRCC, treated with PAZ, in first-line, from June
1st, 2012, when PAZ became available at our center, to March 1st
2016. To be eligible, patients were required to meet the following
inclusion criteria: histologically confirmed mRCC, treatment
with PAZ started between June 1st 2012 andMarch 1st 2016, aged
≥18 years. PAZwas given according to the conventional schedule
of 800mg daily. Last date of follow up was June 1st 2016.
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Statistical Analysis
Descriptive statistics were used to describe baseline
characteristics, treatment patterns and adverse events (AEs).
Categorical variables are described by patient counts and
percentages. PFS by treatment line of therapy was analyzed using
Kaplan-Meier analyses and log rank comparisons Kaplan-Meier
survival curves. The Cox proportional hazards model was used
to test the effect of those variables that reached the statistically
significance at univariate analysis, on survival outcomes in
multivariate analyses. Hazard ratios (HRs) and 95% CIs were
estimated, adjusting for age and gender.
The primary endpoints were progression free survival (PFS)
and OS; the secondary endpoint included the objective response
rate (ORR), the disease control rate (DCR), and the safety profile.
The potential relationships between patients’ characteristics,
AEs and response were also explored. PFS was defined as
the interval between the date of the first dose of PAZ
and the date of the disease progression or death from any
cause; disease progression was defined as radiological tumor
progression according to Response Evaluation Criteria In Solid
Tumors, RECIST (Vogelzang et al., 2015) version 1.1, or clinical
progression, including death. AEs were graded according to
Common Terminology Criteria for AEs version 4.0.
RESULTS
Patient Characteristics
From June 1st 2012 to March 1st 2016, 128 patients with newly
diagnosedmRCC or recurrent RCCwere seen in our department,
124 received a TKI, 45 (36.6%) were treated with PAZ, 38 (30.6%)
were eligible for the final analysis.
In regards to demographics and baseline features, median
age was 61 years old, most patients were male (57.9%), the
87.6% had a Karnofsky Performance Status (Karnofsky PS) ≤
80%, more than half (73.6%), had two or more co-morbidities.
In terms of disease characteristics, the 60.5% underwent to
prior nephrectomy; few patients had a histology different from
clear cell (15.8%); almost all (86.8%) had both bone and
visceral metastases. According to Memorial Sloan-Kettering
Cancer Center Score (MSKCC), the most of patients were
classified as “intermediate” (63.1%) and “good risk” (13.1%),
only 4 patients were “poor risk,” unfit for starting sunitinib
or temsirolimus for multiple and specific co-morbidities
(Table 1).
Clinical Outcomes
The median PFS (mPFS) was 12.7 months (95% CI, 6.9–18.5
months), with median OS (mOS) of 26.2 months (95% CI, 12.6–
39.9 months; Figures 1, 2). The ORR, according to RECIST
criteria version 1.1 (Eisenhauer et al., 2009), was 30.3%, with the
27.3% of patients achieving a partial response, and one patient
having a complete response. The DCR was 72.7% (Table 2). The
median time to best response was 12 weeks. Overall PAZ was
well-tolerated, with no grade 4 toxicity. The most common AEs
were hypertension occurring in the 40.6% of the cases, followed
by dysthyroidism (28.9%) and diarrhea (15.8%). The incidence of
the liver function tests (LFTs) abnormalities (elevations in levels
TABLE 1 | Baseline demographic and clinical patients’ characteristics.
Patient n = 38
Median age, years (range) <70, n (%) 61 (42–79)
≥70, n (%) 17 (44.7%)
21 (55.3%)
Sex male n (%) 22 (57.9%)
female n (%) 16 (42.1%)
PS Karnofsky, n (%) 100–90% 5 (13.1%)
80–70% 27 (71.8%)
≥60% 6 (15.8%)
Comorbidities, n (%) 0 4 (10.5%)
1 6 (15.7%)
2 17 (44.7%)
≥3 11 (28.9%)
Hypertension (%) yes 21 (55.3%)
no 17 (44.7%)
Metastatic disease at diagnosis (%) Yes 19 (50%)
No 19 (50%)
MSKCC/Motzer Score*, n (%) Favorable 5 (13.1%)
Intermediate 24 (63.1%)
Poor 4 (12.5%)
Unknown 0
Prior nephrectomy, n (%) 23 (60.5%)
Time form diagnosis to treatment,
months (range)
13 (1–96)
Hystology, n (%) Clear cell carcinoma 32 (84.2%)
Type I papillary 1 (2.6%)
Type II papillary 2 (5.3%)
Cromophobe 1 (2.6%)
Sarcomatoid variant 2 (5.3%)
Number of metastatic sites, n (%) <6 23 (60.5%)
≥6 15 (39.4%)
Most common metastatic sites, n (%) Lung 21 (55.3%)
Bone 18 (47.4%)
Lymph nodes 16 (42.1%)
Liver 4 (10.5%)
Other 10 (26.3%)
n, number of patients.
*Memorial Sloan-Kettering Cancer Center.
of alanine transaminase [ALT], and/or aspartate transaminase
[AST]) was 26.3%, all events were reversible with an average
recovery of 10 days (Table 3). Some patients required a dose
reduction due to toxicity (23.7%), but approximately the half
of them (45%) was able to go back on the full dose after
regression of the symptoms; none required drug discontinuation
due to side effects (Table 4). Of note, six patients were given
PAZ at 400/600mg daily rather than 800mg due to significant
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FIGURE 1 | Kaplan-Meier curve of median PFS in our cohort of patients
treated with PAZ as first line therapy.
FIGURE 2 | Kaplan-Meier curve of median OS in our cohort of patients
treated with PAZ as first line therapy.
co-morbidities apparently without any effect on the outcome,
reaching 20 months as maximum duration of treatment.
PFS appeared to not be influenced by number of co-
morbidities (<3 vs. ≥3), gender, Fuhrman grade and age
(Table 5). A longer mPFS, that not reached the statistically
significance, was seen in patients with only bone vs. visceral
metastases vs. both (17.4 vs. 12.7 vs. 12.1 months; 95% CI,
1.6–26.4 months; p = 0.7). A worse mPFS was achieved in
patients with liver metastases (mPFS 5.9 vs. 12.7 months; 95%
CI, 3.5–18.4; p = 0.2) and with higher tumor burden (number
of metastatic sites <6 vs. ≥6) with mPFS 19.2 vs. 6.3 months
(p= 0.08). Patients that gained a higher ORR andDCR had better
TABLE 2 | Objective response with PAZ in our study population.
Patient n = 38
BEST RESPONSE, n (%)
CR 1 (3%)
PR 9 (27.3%)
SD 14 (42.4%)
PD 9 (27.3%)
Not available* 5 (15.5%)
ORR (CR + PR), n (%) 10 (30.3%)
DCR (CR + PR + SD) n (%) 24 (72.7%)
n, number of patients; CR, complete response; PR, partial response; SD, stable disease;
PD, progressive disease; ORR, objective response rate; DCR, disease control rate.
*not available at the time of the analysis.
TABLE 3 | Adverse events of first-line PAZ in our study population.
All grades Grade 3/4
Hypertension 13 (40.6%) 4 (10.5%)
Dysthyroidism 11 (28.9 %) 1 (2.6%)
Alteration of liver function 10 (26.3%) 6 (15.7%)
Diarrhea 6 (15.8%) 0
Mucositis 4 (13.1%) 1 (2.6%)
Fatigue 4 (10.5%) 0
Anemia 4 (10.5%) 1 (2.6%)
TABLE 4 | Dose modification and/or interruption due to adverse events.
Dose reductions n, % 9 (23.7%)*
Treatment interruptions n, % 0
n, number of patients. * ∼45% of patients received a subsequent re-escalation of dose
within 3 weeks.
outcomes in terms of bothmPFS (HR= 0.05 [95%CI, 0.05–0.55],
p= 0.01; HR= 0.10, [95% CI, 0.02–0.43, p= 0.002, respectively;
Table 6A), but not in terms of mOS (p = 0.2; p = 0.35,
respectively; Table 5). No statistically significant differences in
mPFS was observed according to histology (p = 0.3; Table 5).
As expected, the prior nephrectomy positively influenced the OS
compared to no prior surgery (HR = 0.32 [95% CI, 0.09–1.07],
p= 0.06; Table 6B). Worst OS was observed in patients aged≥70
years old (HR = 6.91 [95% CI, 1.49–31.91], p = 0.01; Table 6B),
but Karnofsky PS did not influence PAZ efficacy (HR= 1.65 [95%
CI, 0.39–7.0], p= 0.5; Table 6B).
The impact of the hypertension seemed to be predictive
of a prolonged survival, that was greater in patients that
experienced a grade 3 event according to CTCAE v4.0 (HR= 0.22
[95% CI, 0.05–0.8], p = 0.03; Table 6B), but not in terms
of mPFS (p = 0.6; Table 5). In addition, tumor response
was influenced by hypertension tough four, among the five
patients who developed grade 3 hypertension (80%), had PR.
The hepatotoxicity not influenced the mPFS (p = 0.6) and OS
significantly (p = 0.8; Table 5). The occurrence of a thyroid
dysfunction (hypo-hyperthyroidism) during treatment with PAZ
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TABLE 5 | Univariate analysis of PFS and OS in our study population
(N = 38).
PFS OS
p-value p-value
GENDER 0.3 0.2
Male/Female
N◦ OF COMORBIDITIES 0.8 0.8
<3/≥3
HYSTOLOGY 0.3 0.8
Clear Cells/Other
AGE 0.4 0.003
<70 years/≥70 years
KARNOFSKY PS 0.2 0.02
<80%/≥80%
PRIOR NEPHRECTOMY 0.6 0.03
Yes/No
METASTATIC OF SITES 0.08 0.4
≤5/≥6
DYSTHYROIDISM 0.04 0.8
No/Yes
HYPERTENSION 0.6 0.02
No/G1-2/G≥3
HEPATOTOXICITY 0.6 0.8
G1-2/G≥3/No Toxicity
TUMOR RESPONSE RATE 0.002 0.2
DCR 0.0001 DCR
DCR (CR + PR + SD)/PD
PFS, progression-free survival; OS, overall survival; CR, complete response; PR, partial
response; SD, stable disease; PD, progressive disease; DCR, disease control rate; PS,
performance status.
resulted in a prolonged mPFS (HR = 0.12 [95% CI, 0.02–0.78],
p= 0.02; Table 6A) but not mOS (p= 0.8; Table 5).
Outcome in Non-clear Cell Histology
A small percentage (15.8%) of our population, 6 patients, had
a histology different from clear cell. One patient had a type I
papillary tumor; two had a type II papillary tumor; one had a
chromophobe; two a sarcomatoid variant of renal cancer. PAZ
has been active and well-tolerated with 3 patients achieving PR
and 3 SD, the median duration of treatment in such subgroup
has been 9.3 months, the mPFS of 10.6 months (95% CI, 4.4–16.8
months).
DISCUSSION
Randomized clinical trials are the gold standard to evaluate the
efficacy of a new treatment within a specified patient population
and the available international guidelines for physicians for
treatment of mRCC essentially reflect the evidences for the
different agents emerged from the respective clinical trial
(AIOM, 2015; ESMO, 2015; NCCN, 2015). Nevertheless, the
populations included in pivotal clinical trials are highly selected
(no relevant co-morbidities, no poor performance status, no
atypical metastases [e.g., brain metastases] or no histo-types
Table 6A | Multivariate adjusted Cox model for progression-free survival.
Progression-free survival
HR* (95% CI) p-value
DYSTHYROIDISM
Yes 0.12 (0.02–0.78) 0.02
ORR
(RC + RP) 0.05 (0.05–0.55) 0.01
DCR
(RC + RP + SD) 0.10 (0.02–0.43) 0.002
HR, hazard ratio; 95% CI: 95% confidence interval; *Multivariate Cox model adjusted for
age and gender.
Table 6B | Multivariate adjusted Cox model for overall survival.
Overall survival
HR* (95% CI) p-value
AGE
≥70 years 6.91 (1.49–31.91) 0.01
KARNOFSKY PERFORMANCE STATUS
<80% 1.65 (0.39–7.0) 0.5
NEPHRECTOMY
Yes 0.32 (0.09–1.07) 0.06
HYPERTENSION
≥G3 0.22 (0.05–0.8) 0.03
HR, hazard ratio; 95% CI: 95% confidence interval; *Multivariate Cox model adjusted for
age and gender.
different from clear cell) and generally have better outcomes
compared to patients who are ineligible for such studies (Molina
and Motzer, 2011; Heng et al., 2014). Therefore, it is not always
simple to transfer the clinical trials results into clinical practice
due to the large proportion of patients who are routinely treated
in our clinics but would be judged ineligible in the pivotal trials.
The optimization of the disease management should be based on
clinical trials but also on real experiences (Schmidinger et al.,
2013). Such registries, also known as “real world” or “real life”
studies, providing insights into treatment patterns and outcomes,
are emerging as a crucial tool for the clinicians because of a major
reproducibility compared with randomized trials (Shek et al.,
2012; Ta et al., 2013; Vaishampayan et al., 2014).
In terms of mPFS, we observed a median of 12.7 months,
which is longer than the one reported in the COMPARZ (Motzer
et al., 2013a) trial (8.4 months) and similar to the one detected
in the pivotal phase III trial for the group of treatment-naïve
patients (Sternberg et al., 2010). Looking at the different “real
world” experiences, the mPFS was 8.5 months in the Vogelzang
et al. (2015) analysis, 13.7 months in the MD Anderson Cancer
Center study 17 (Matrana et al., 2013a), and 13.0 months in
the Christie study (Galvis et al., 2013), in which the 74% of the
patients receiving PAZ was treatment-naïve. The variations in
the mPFS observed in these studies could have resulted from
varying operational definitions of PFS such as different timing
and frequency of disease assessment.
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Comparing the data about survival, we noted that our median
OS, 26.2 months, was longer than the ones observed in other
studies, the pivotal trial (22.9 months), in the Christie study
(19 months; Galvis et al., 2013), Vogelzang NJ et al analysis
(22 months) (Vogelzang et al., 2015), and similar to the ones
detected in the COMPARZ trial (28.4 months; Motzer et al.,
2013a) and in the MD Anderson “real life” study (29.1 months;
Matrana et al., 2013a). ORR and DCR appeared similar when
compared to the outcomes of the randomized, phase III trial. We
have been comforted by PAZ activity, therefore is not obvious to
consider that patients with greater DCR and objective response
obtained an improvement in OS and PFS. It is interesting to note
that Karnofsky PS not influenced the OS, in contrast previous
nephrectomy and an age ≤70 year old impact positively.
Overall our findings are very encouraging especially
considering that the population was totally unselected, with a
large proportion of frail patients, presenting more unfavorable
prognostic factors (multiple co-morbidities, high tumor burden,
worse PS and lower number of nephrectomies) compared to the
available literature; our efficacy data are substantially consistent
with those reported in both the prospective phase III trials and
the retrospective analyses (Galvis et al., 2013; Matrana et al.,
2013a,b; Motzer et al., 2013a,b; Sternberg et al., 2013; Jonasch
et al., 2014; Vogelzang et al., 2015).
In regards to tolerability, we reported a safety profile
slightly better compared with the other experiences. In our
cohort, no grade 4 toxicity occurred and no permanent drug
discontinuations due to toxicity were required. Furthermore, the
rate of dose reductions due to AEs was 28%, but up to 45%
received a subsequent re-escalation of dose.
Themost frequent AEwas hypertension observed in the 40.6%
of the cases, such rate is similar to the ones observed in the
COMPARZ (46%; Motzer et al., 2013a) and in the phase III
pivotal trial (40%) (Sternberg et al., 2010), but superior to the
one reported in the MD Anderson study (Matrana et al., 2013a)
(21%) and in the analysis by Vogelzang et al. (2015) (27%). It is
important to underline that about 25% of patients had poorly
controlled hypertension at the times beginning PAZ, compared
to the phase III trials. This medical condition was not related to a
higher risk of cardiac toxicity during PAZ treatment, supporting
its use even in this subset. The differences in hypertension
incidence across the studies might have arisen from closer
monitoring of vital signs during our study protocol according
to the clinical trials. In contrast, the rates of fatigue (10.5%)
and diarrhea (15.8%) were lower than previously reported: the
MD Anderson study (Matrana et al., 2013a), 58 and 39%,
respectively; Vogelzang analysis (Vogelzang et al., 2015), 56 and
52%, respectively; COMPARZ (Motzer et al., 2013a): 55 and 63%,
respectively; Phase III trial: 19 and 52%, respectively (Sternberg
et al., 2010). These differences in the incidence of fatigue are likely
to be due both to the variability of the evaluation criteria adopted
and to the retrospective nature of our data which probably led to
an underestimation of the toxicities, especially the ones that are
subjectively evaluated such as fatigue/asthenia.
The incidence of hepatic impairment was as expected (26.3%),
the elevation of the liver function tests of grade 3 involved only 6
patients, and this event has been reversible and was not related to
liver metastasis or other liver illness.
Six patients were treated with a lower dose of PAZ for
concomitant diseases for the entire duration of treatment; we
found that dose reduction was not associated with reduced
efficacy, suggesting that the personalization of the drug schedule
and the early management of the emerging toxicities represent
crucial steps to maximize the therapeutic benefit.
We failed to identify predictive factors of response, although
the occurrence of a thyroid dysfunction and grade 3 hypertension
seemed to be related to a prolonged PFS and OS, respectively.
The use of PAZ out of clinical trial allowed us to evaluate
its activity also in a subset of patients with histology other
than clear cell, usually excluded from academic studies for
their poor prognosis and limited sensibility to anticancer
drugs. Our patients were not candidate for sunitinib and or
temsirolimus treatment due to several specific co-morbidities.
PAZ demonstrated to be still active also in this subset of patents
with a mPFS of 10.6 months (95% CI, 4.4–16.8 months), data
that are longer compared to those from pivotal phase III trial of
sunitinib, and that will probably contribute to enrich the very few
anecdotal literature data.
CONCLUSIONS
Our results are consistent with those reported in prospective
phase III trials and the published retrospective “real world”
experiences. This analysis confirm the safety and efficacy of
PAZ in first-line setting, both in frail patients with multiple co-
morbidities and Karnofsky PS < 80% and in younger, healthier
patients with number of metastatic sites<6. Thyroid dysfunction
and hypertension may represent prognostic factors for longer
PFS and OS, respectively. More extensive data and larger
sample are needed in order to appropriately guide real-world
practice.
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